Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior.
AIDS
; 18(5): 787-92, 2004 Mar 26.
Article
em En
| MEDLINE
| ID: mdl-15075514
ABSTRACT
BACKGROUND:
The effectiveness of postexposure prophylaxis (PEP) following occupational exposure to HIV has prompted advocacy for PEP following sexual or drug-use exposures.OBJECTIVE:
To evaluate the concern that the availability of PEP for sexual or drug-use exposures might result in behavioral disinhibition.DESIGN:
Non-randomized trial of 397 adults with high-risk sexual or drug-use exposures within the prior 72 h.INTERVENTIONS:
Antiretroviral medication for 4 weeks and five counseling sessions. MAIN OUTCOME MEASUREMENTS Participants were followed for 12 months for repeat request for PEP and for changes compared with pre-enrollment in overall high-risk behavior and the acquisition of sexually transmitted diseases (STD) and HIV.RESULTS:
After 12 months following receipt of PEP, the majority of participants (83%) did not request a repeat course of PEP. At 12 months after exposure, 73% of participants reported a decrease compared with baseline in the number of times they had performed high-risk sexual acts; 13% reported no change, and 14% had an increase. Most participants (85%) had no change in the incidence of STD; 8.5% had a decrease and 6.8% an increase. Three homosexual men seroconverted for HIV (none associated with the presenting exposure) for a rate of 1.2/100 person-year, equivalent to rates in San Francisco among all homosexual men.CONCLUSIONS:
After receipt of PEP consisting of antiretroviral medication and behavioral counseling following a potential sexual exposure to HIV, most individuals do not increase high-risk behavior. Coupled with prior safety and feasibility data, this lack of behavioral disinhibition suggests that use of PEP should be routinely considered following high-risk sexual exposures.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Assunção de Riscos
/
Comportamento Sexual
/
Infecções por HIV
/
Fármacos Anti-HIV
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
AIDS
Assunto da revista:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Ano de publicação:
2004
Tipo de documento:
Article
País de afiliação:
Estados Unidos